
Autonomous VTOL delivery solutions.
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about Volansi (W17).
Volansi built impressive long-range delivery drones and ran pilots with Merck, Boeing, and the U.S. military — and still ran out of runway before the market it needed could legally exist. Founded in 2015 in the San Francisco Bay Area by Hannan Parvizian and Wesley Zheng, it made vertical-takeoff-and-landing (VTOL) drones for middle-mile logistics: flying medical supplies, spare parts, and defense payloads long distances autonomously.[1]
The company raised roughly $75 million, including a $50 million round, and in March 2022 unveiled the VOLY 50, a long-range flexible-payload drone slated for low-rate production in 2023.[2][3] Months later it was gone: in July 2022 Volansi filed an assignment for the benefit of creditors and ceased operations.[1] The core problem wasn't the aircraft. It was that commercial drone delivery at scale required routine beyond-visual-line-of-sight flight the FAA had not yet authorized, so Volansi's revenue ceiling was set by a regulator's timeline while its burn was set by its own ambition.
Hannan Parvizian and Wesley Zheng founded Volansi (originally styled Volans-i) in 2015 to solve a real logistics gap: getting critical goods across the "middle mile" — tens or hundreds of miles between a warehouse or port and a remote site — faster and cheaper than trucks or helicopters.[5] For medical supplies to clinics, spare parts to ships or oil rigs, and resupply to military units, a fast autonomous aircraft could be transformative.
The founders bet on hybrid VTOL drones: aircraft that take off and land vertically like a helicopter but fly efficiently like a fixed-wing plane, giving both landing flexibility and long range. The vision attracted serious partners and capital — Volansi ran vaccine-delivery pilots with pharmaceutical giant Merck, drew investment interest from Boeing, and secured work with the U.S. Department of Defense.[6] These relationships validated that the capability was wanted. But they were pilots and contracts of exploration, not the scaled commercial volume the business needed, and the gap between "prestigious pilot" and "recurring revenue at scale" is where Volansi lived and eventually died.
Volansi built a family of autonomous VTOL cargo drones under the VOLY name. The aircraft could take off vertically from a small pad, transition to efficient winged flight to cover long distances, deliver a payload, and return — all autonomously, without a runway or a pilot on the sticks.[3] The final flagship, the VOLY 50, emphasized long range and a flexible payload bay so a single airframe could serve medical, commercial, and defense missions.[7]
The engineering was legitimate and the use cases compelling: delivering vaccines to hard-to-reach clinics, resupplying ships at sea, or moving parts to remote industrial sites. But building and iterating aircraft is expensive and slow, and each new model consumed capital while the path to flying them commercially at scale remained blocked. Volansi was developing hardware as fast as its funding allowed toward a market whose gate — routine long-range autonomous flight over populated areas — only a regulator could open.[8]
Volansi targeted enterprise and government buyers with remote-logistics pain: pharmaceutical and healthcare distribution, industrial and offshore operators, and the military — customers with real need and budget, but who bought in pilots and programs, not yet in fleets.
Read the complete post-mortem, the rebuild playbook, and the exact reasons Volansi is still worth studying now.